Tyr1250
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Phosphorylation Site Page:
Tyr1250 - HER2 (rat)

Site Information
PTAENPEyLGLDVPV    SwissProt Entrez-Gene
Predicted information: Scansite
Orthologous residues: HER2 (human): Y1248, HER2 (mouse): Y1249, HER2 iso2 (human): Y638
Blast this site against: NCBI  SwissProt  PDB 

In vivo Characterization
Methods used to characterize site in vivo: flow cytometry (2), immunoprecipitation (1), microscopy-colocalization with upstream kinase (8), mutation of modification site (2, 7, 8, 10), phospho-antibody (1, 2, 3, 4, 5, 6, 9), western blotting (1, 2, 3, 4, 8)
Disease tissue studied: breast cancer (2, 8), diabetes mellitus (1)
Relevant cell line - cell type - tissue: 'muscle, smooth'-thoracic aorta (6), 3T3 (fibroblast) (10), cholangiocyte (5), COS (fibroblast) (8), G8/DHFR (fibroblast) (9), heart (3), MCF-10A (breast cell) (2), MCF-7 (breast cell) (8), MDCK (epithelial) (2), Rat1 (fibroblast) (7), Schwann (4, 9), vascular (1), VSMC (1)

Controlled by
Putative upstream kinases: HER2 (rat) (2)
Treatments: AG825 (1, 4), AP1510 (2), betacellulin (6), EGF (8), heart failure (3), laminin-1 (4), nerve damage (9), neuregulin (3, 4), phorbol ester (9)

Downstream Regulation
Effects of modification on HER2: molecular association, regulation (6, 8)
Effects of modification on biological processes: cell growth, altered (10)
Induce interaction with: Chk1 (rat) (8), EGFR (rat) (6)

Disease / Diagnostics Relevance
Relevant diseases: breast cancer (8)

References

1

Akhtar S, et al. (2013) Activation of ErbB2 and Downstream Signalling via Rho Kinases and ERK1/2 Contributes to Diabetes-Induced Vascular Dysfunction. PLoS One 8, e67813
23826343   Curated Info

2

Lucs AV, Muller WJ, Muthuswamy SK (2010) Shc is required for ErbB2-induced inhibition of apoptosis but is dispensable for cell proliferation and disruption of cell polarity. Oncogene 29, 174-87
19826412   Curated Info

3

Doggen K, et al. (2009) Ventricular ErbB2/ErbB4 activation and downstream signaling in pacing-induced heart failure. J Mol Cell Cardiol 46, 33-8
19010331   Curated Info

4

Thaxton C, Lopera J, Bott M, Fernandez-Valle C (2008) Neuregulin and laminin stimulate phosphorylation of the NF2 tumor suppressor in Schwann cells by distinct protein kinase A and p21-activated kinase-dependent pathways. Oncogene 27, 2705-15
17998937   Curated Info

5

Lai GH, et al. (2005) erbB-2/neu transformed rat cholangiocytes recapitulate key cellular and molecular features of human bile duct cancer. Gastroenterology 129, 2047-57
16344070   Curated Info

6

Mifune M, et al. (2004) Signal transduction of betacellulin in growth and migration of vascular smooth muscle cells. Am J Physiol Cell Physiol 287, C807-13
15163624   Curated Info

7

Dankort D, et al. (2001) Multiple ErbB-2/Neu Phosphorylation Sites Mediate Transformation through Distinct Effector Proteins. J Biol Chem 276, 38921-8
11500516   Curated Info

8

Zrihan-Licht S, et al. (1998) Csk homologous kinase, a novel signaling molecule, directly associates with the activated ErbB-2 receptor in breast cancer cells and inhibits their proliferation. J Biol Chem 273, 4065-72
9461599   Curated Info

9

Kwon YK, et al. (1997) Activation of ErbB2 during wallerian degeneration of sciatic nerve. J Neurosci 17, 8293-9
9334404   Curated Info

10

Mikami Y, et al. (1992) Carboxyl-terminal deletion and point mutations decrease the transforming potential of the activated rat neu oncogene product. Proc Natl Acad Sci U S A 89, 7335-9
1354355   Curated Info

Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.